| 23.99 -0.38 (-1.56%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.4 |
1-year : | 36.76 |
| Resists | First : | 28.6 |
Second : | 31.47 |
| Pivot price | 28.42 |
|||
| Supports | First : | 23.95 |
Second : | 19.92 |
| MAs | MA(5) : | 26 |
MA(20) : | 28.21 |
| MA(100) : | 29.74 |
MA(250) : | 27.77  |
|
| MACD | MACD : | -0.8 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 2.4 |
D(3) : | 15.2 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 38.25 | Low : | 20.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BEAM ] has closed below the lower bollinger band by 1.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BEAM ] is to continue within current trading range. Bollinger Bands are 19.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.76 - 24.93 | 24.93 - 25.06 |
| Low: | 23.5 - 23.73 | 23.73 - 23.91 |
| Close: | 23.67 - 23.98 | 23.98 - 24.22 |
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Fri, 11 Sep 2026
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Thu, 10 Sep 2026
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
Thu, 10 Sep 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM - PR Newswire
Thu, 10 Sep 2026
BEAM: Durable gene editing advances in AATD, PKU, and sickle cell drive clinical and commercial momentum - TradingView
Wed, 09 Sep 2026
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 103 (M) |
| Held by Insiders | 8.824e+007 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 23,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.5578e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -55.5 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 827.1 % |
| Return on Equity (ttm) | -17.1 % |
| Qtrly Rev. Growth | 1.5604e+008 % |
| Gross Profit (p.s.) | -42.25 |
| Sales Per Share | -3.67 |
| EBITDA (p.s.) | -1.13287e+008 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -359 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -6.55 |
| Price to Cash Flow | 5 |
| Dividend | 0 |
| Forward Dividend | 2.437e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|